Literature DB >> 16210492

Humoral and cellular immunity in children with Mycoplasma pneumoniae infection: a 1-year prospective study.

Iwona Stelmach1, Malgorzata Podsiadłowicz-Borzecka, Tomasz Grzelewski, Pawel Majak, Wlodzimierz Stelmach, Joanna Jerzyńska, Marta Popławska, Jaroslaw Dziadek.   

Abstract

To determine whether children have persistent abnormalities in cellular and humoral immunity development after acute Mycoplasma pneumoniae infection, serum immunoglobulin G (IgG), IgA, IgM, and IgE levels and lymphocyte phenotypes were determined. There were no changes in the levels of IgG, IgM, IgA, or CD4+ or CD19+ lymphocytes that were measured in M. pneumoniae-positive patients after 3 months or after 12 months, but there were increases in these in M. pneumoniae-negative patients. Serum IgE increased in M. pneumoniae-positive patients. We have shown alterations in immunity development after M. pneumoniae infection.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16210492      PMCID： PMC1247828          DOI： 10.1128/CDLI.12.10.1246-1250.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  21 in total

1.  [Cellular immunity and epidemiologic analysis of pediatric patients with Mycoplasma pneumonia].

Authors:  H Zhao; L Li; X Liu
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  1999-02

2.  Levels of interleukin-2, interferon-gamma, and interleukin-4 in bronchoalveolar lavage fluid from patients with Mycoplasma pneumonia: implication of tendency toward increased immunoglobulin E production.

Authors:  Y Y Koh; Y Park; H J Lee; C K Kim
Journal:  Pediatrics       Date:  2001-03       Impact factor: 7.124

3.  Mycoplasma pneumoniae-associated Stevens-Johnson syndrome exhibits lymphopenia and redistribution of CD4+ T cells.

Authors:  Lin Wang; Kuo-Ching Hong; Fu-Chein Lin; Kuender D Yang
Journal:  J Formos Med Assoc       Date:  2003-01       Impact factor: 3.282

4.  Circulating immune complexes in Mycoplasma pneumoniae infection.

Authors:  G Biberfeld; R Norberg
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

5.  Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults.

Authors:  Hiroshi Tanaka; Mitsuo Narita; Shin Teramoto; Toyohiro Saikai; Kensuke Oashi; Tomofumi Igarashi; Shosaku Abe
Journal:  Chest       Date:  2002-05       Impact factor: 9.410

6.  Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing.

Authors:  S Esposito; F Blasi; C Arosio; L Fioravanti; L Fagetti; R Droghetti; P Tarsia; L Allegra; N Principi
Journal:  Eur Respir J       Date:  2000-12       Impact factor: 16.671

7.  Mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice.

Authors:  Monica Fonseca-Aten; Ana M Ríos; Asunción Mejías; Susana Chávez-Bueno; Kathy Katz; Ana M Gómez; George H McCracken; R Doug Hardy
Journal:  Am J Respir Cell Mol Biol       Date:  2004-12-30       Impact factor: 6.914

8.  [T(H1) and T(H2) cells in children with mycoplasma pneumonia].

Authors:  An-cun Hou; Yan Lu; Li Sha; Li-ge Liu; Jing Shen; Yong Xu
Journal:  Zhonghua Er Ke Za Zhi       Date:  2003-09

9.  [Evaluation of factors associated with recurrent and/or severe infections in patients with Down's syndrome].

Authors:  Luciana M A Ribeiro; Cristina M A Jacob; Antonio C Pastorino; Chong A E Kim; Angela B F Fomin; Ana Paula B M Castro
Journal:  J Pediatr (Rio J)       Date:  2003 Mar-Apr       Impact factor: 2.197

10.  [Serum immunoglobulin in Mycoplasma pneumoniae infection].

Authors:  M S Baĭzhomartov; I Kh Shuratov; V A Semenova; G U Diuskalieva; O G Stetsenko
Journal:  Zh Mikrobiol Epidemiol Immunobiol       Date:  1985-02
View more
  8 in total

Review 1.  Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

Authors:  I Steiner; G Rosenberg; I Wirguin
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

2.  Characteristics of respiratory syncytial virus-induced bronchiolitis co-infection with Mycoplasma pneumoniae and add-on therapy with montelukast.

Authors:  Sheng-Hua Wu; Xiao-Qing Chen; Xia Kong; Pei-Ling Yin; Ling Dong; Pei-Yuan Liao; Jia-Ming Wu
Journal:  World J Pediatr       Date:  2015-04-06       Impact factor: 9.186

3.  Clinical significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia.

Authors:  Soojeong Choo; Yun Young Lee; Eun Lee
Journal:  BMC Pulm Med       Date:  2022-05-30       Impact factor: 3.320

4.  Epidemiology and associations with climatic conditions of Mycoplasma pneumoniae and Chlamydophila pneumoniae infections among Chinese children hospitalized with acute respiratory infections.

Authors:  Zhengrong Chen; Wei Ji; Yuqing Wang; Yongdong Yan; Hong Zhu; Xuejun Shao; Jun Xu
Journal:  Ital J Pediatr       Date:  2013-05-25       Impact factor: 2.638

5.  Suppression of antimicrobial peptide expression by ureaplasma species.

Authors:  Li Xiao; Donna M Crabb; Yuling Dai; Yuying Chen; Ken B Waites; T Prescott Atkinson
Journal:  Infect Immun       Date:  2014-02-03       Impact factor: 3.441

6.  Mycoplasma pneumoniae Seroprevalence and Total IgE Levels in Patients with Juvenile Idiopathic Arthritis.

Authors:  Dimitri Poddighe; Diyora Abdukhakimova; Kuanysh Dossybayeva; Zaure Mukusheva; Maykesh Assylbekova; Marzhan Rakhimzhanova; Aigul Ibrayeva; Gaukhar Mukash; Yernas Tuleutayev
Journal:  J Immunol Res       Date:  2021-10-06       Impact factor: 4.818

7.  Is There any Relationship Between Extra-Pulmonary Manifestations of Mycoplasma Pneumoniae Infection and Atopy/Respiratory Allergy in Children?

Authors:  Dimitri Poddighe; Gian Luigi Marseglia
Journal:  Pediatr Rep       Date:  2016-03-31

8.  Correlation Between the Clinical Severity, Bacterial Load, and Inflammatory Reaction in Children with Mycoplasma Pneumoniae Pneumonia.

Authors:  Chen Zhang; Qiao Zhang; Jie-Lin Du; Dan Deng; Ye-Lei Gao; Cheng-Lin Wang; Hong-Jie Zhao; Qian Guo; Zhou Fu; Dai-Yin Tian
Journal:  Curr Med Sci       Date:  2020-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.